Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2013. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the closing middle market price of an Ordinary Share on August 27, 2013, which was £16.77.
Material Changes
The filing details a change in share interests for Mrs. V Whyte, a PDMR. She acquired 13,070 Ordinary Shares on August 27, 2013, resulting from an award under the GlaxoSmithKline 2009 Share Value Plan. No other material changes to the company's financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of a specific executive share transaction.
Investor Verification Points
- Verify the total shareholding of Mrs. V Whyte post-transaction to assess concentration of ownership.
- Confirm the terms of the GlaxoSmithKline 2009 Share Value Plan regarding vesting and performance conditions.
- Review the company's Form 20-F for the full financial performance data for the period, as this 6-K does not contain it.